Nonhuman Primate Reagent Resource
Document text
Principal Investigator: Kathleen Engelman Organization: UNIV OF MASSACHUSETTS MED SCH WORCESTER Fiscal Year: 2020 Award: $353,732 Funding agency: National Institute of Allergy and Infectious Diseases U24 AI126683 – Parent Award Abstract Nonhuman primates (NHPs) serve a crucial role in translational research as animal models for exploring the pathogenesis of infectious and noninfectious diseases, and for testing of biologic therapies and vaccines. While many human diagnostic immunologic reagents cross react with the primate species commonly employed in translational research, gaps exist for a substantial number of reagent targets. Furthermore, antibodies that target specific immune functions or deplete specific lymphocyte subpopulations in vivo have proven valuable in defining disease mechanisms or can be used as proof-of-concept for new therapies. For the past 15 years, the NIH Nonhuman Primate Reagent Resource has responded to needs of the scientific community by developing, manufacturing and distributing NHP-specific reagents for in vitro diagnostics and for in vivo use. Utilization of this resource has grown dramatically since this program’s inception. During the last budget year, we fulfilled 500 reagent requests from 126 investigators and distributed over 300 grams of recombinant antibody for administration to NHPs. Taking advantage of scientific advances and technological improvements in antibody development, engineering, expression and vectoring, we will continue to support the scientific community utilizing NHP models across all scientific disciplines. Terms: <2019 novel coronavirus><2019-nCoV><Address><Animal Model><Animal Models and Related Studies><Antibodies><Assay><Award><Bioassay><Biologic Assays><Biologic Therapy><Biological Assay><Biological Response Modifier Therapy><Biological Testing><Biological Therapy><Bioreactors><Budgets><COVID-19><COVID19><Cell Body><Cells><Cellular Immune Function><Communicable Diseases><Communities><Detection><Development><Diagnostic><Discipline><Disease><Disorder><Engineering><Future><Human><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><In Vitro><Industrialization><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Infrastructure><Investigators><Lymphocyte Subpopulations><Lymphocyte Subset><Methodology><Methods><Microbiology><Modeling><Modern Man><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Parents><Pathogenesis><Primates><Primates Mammals><Production><Proteins><Reagent><Recombinant Antibody><Recombinants><Research><Research Personnel><Research Resources><Researchers><Resources><Role><Running><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Scientific Advances and Accomplishments><Serologic><Serological><Severe acute respiratory syndrome coronavirus 2><Survey Instrument><Surveys><Test Result><Time><Translational Research><Translational Science><United States National Institutes of Health><Vaccines><Viral><Viral Antigens><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Wuhan coronavirus><biological therapeutic><biological treatment><biotherapeutics><biotherapy><corona virus disease 2019><coronavirus disease 2019><depository><developmental><experience><expression vector><immune function><in vivo><manufacturing process><model of animal><model organism><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><non-human primate><nonhuman primate><novel drug treatments><novel drugs><novel therapeutics><novel therapy><programs><repository><scientific accomplishments><scientific advances><social role><tool><translation research><virus antigen><virus protein>